All In Biotech

NDA 208025 · Dexcel

Lansoprazole

Lansoprazole · Oral · Proton Pump Inhibitor

Last checked: Nov 20, 2026Latest source record: Mar 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jun 7, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

288

83 Phase 3, 12 recruiting

FAERS reports

107,664

99,937 serious, 13,581 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2026.

Use • treats frequent heartburn (occurs 2 or more days a week) • not intended for immediate relief of heartburn; this drug may take 1 to 4 days for full effect

Therapeutic areas: Gastroenterology and liver

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 7, 2016 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetter
1 products under this application
  • LANSOPRAZOLE · LANSOPRAZOLE 15MG · TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Lansoprazole" as an intervention, any sponsor and status, largest first.

All 288 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea6,722
  • dyspnoea6,053
  • nausea5,778
  • off label use5,446
  • fatigue5,367
  • vomiting5,281
  • acute kidney injury5,012
  • malaise4,796
  • headache4,788
  • chronic kidney disease4,679
  • pyrexia4,606
  • dizziness4,143

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,299
20051,407
20061,111
20071,295
20081,663
20091,688
20101,874
20112,666
20123,288
20132,962
20143,515
20154,950
20165,797
20175,516
20188,294
201910,604
20207,738
20216,769
20226,859
20237,552
20248,133
20257,421
20265,262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lansoprazole (Lansoprazole)

2024 spending

$47.3M

Beneficiaries

324,506

1,231,347 claims

Per beneficiary

$146

$0.61 per unit

View as table
YearSpending
2020$55,859,283
2021$62,952,966
2022$71,415,486
2023$57,025,404
2024$47,285,025

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 932 on PubMed

Sponsor: Dexcel

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.